Login to Your Account

BioLineRx Swoons on Halt in Schizophrenia Drug Trial

By Marie Powers
Staff Writer

Thursday, March 21, 2013

Schizophrenia claimed another victim Wednesday as shares of BioLineRx Ltd. plummeted after the company halted the Phase II/III CLARITY trial of BL-1020, its first-in-class, orally available GABA-enhanced antipsychotic and the lead program in the company's diverse pipeline.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription